Stargardt Disease clinical trials at UC Health

• Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease

  open to eligible people ages 8-70

  The purpose of this study is to determine the long term safety and tolerability of ALK-001 (C20-D3-retinyl acetate), and to explore the effects of ALK-001 on the progression of Stargardt disease in patients between the ages of 8 and 70 years old. Funding Source - FDA OOPD

  at UCLA

• Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)

  open to eligible people ages 18-50

  To evaluate the safety and efficacy of Zimura™ (complement factor C5 inhibitor) compared to Sham in subjects with autosomal recessive Stargardt disease 1 (STGD1).

  at UCLA

• Safety and Efficacy of Emixustat in Stargardt Disease

  Sorry, in progress, not accepting new patients

  The purpose of this study is to determine if emixustat hydrochloride reduces the rate of progression of macular atrophy compared to placebo in subjects with Stargardt disease. Funding Source -- FDA OOPD

  at UCSF

Last updated: January 14, 2021